yes i take peptides · shopping companion
SS-31 (Elamipretide)
Forzinity / SS-31
Category · For LongStatus · FDACitations · 60
The verdict
Yes for trial-eligible mitochondrial disease patients — no for healthy-adult longevity use.
By source — cost, legality, risk
- Brand — Forzinity (Stealth Biotherapeutics)~$200,000+/year via specialty pharmacyFDA-approved Sept 2025 · Barth syndrome onlyLowest molecular. Ultra-rare-disease pricing; only realistic for diagnosed Barth patients with insurance coverage.
- Compounded 503A pharmacyNot meaningfully availableNot available — no 503A path post-approvalPost-approval, 503A compounding is closed; brand or RUO are the only realistic channels.
- RUO research peptide$80–$300/mo at community 1–4mg/dSold 'for research only'Highest. The D-amino acid stereochemistry matters for activity; RUO product made with all-L is a different molecule. Chiral HPLC rarely run.
- Gray-market raw$25–$125/moUnregulated overseas importCrypto/Wise pay; same D-stereochemistry concern as RUO; identity verification by mass spec alone is insufficient.
Stop signals · abort if
- persistent severe injection-site reaction
- any new cardiac symptom (in cardiomyopathy population)
- allergic reaction
- any new mass or unexplained pain
Sources · top 5 of 60
- 01Zhao W, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Journal of neuroinflammation. 2019;16(1):230. PMID: 31747905.
- 02Zheng H, et al. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025;183:117832. PMID: 39848110.
- 03Nie Y, et al. Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages. Antioxidants (Basel, Switzerland). 2023;12(12). PMID: 38136142.
- 04Whitson JA, et al. Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins. GeroScience. 2021;43(5):2395-2412. PMID: 34480713.
- 05Tung C, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences. 2025;26(3). PMID: 39940712.